An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Women whose breast cancers need estrogen to grow are often treated for five or more years with medications to lower estrogen production or block its effects. Broadly known as endocrine therapy, the ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Captain Wild Bill Wichrowski has been open with Deadliest Catch fans about his cancer battle. Here's the latest update.

The American Cancer Society estimates that 67,400 Americans will be diagnosed with pancreatic cancer this year and nearly ...

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

In this video, Aruna Padmanabhan, MD, discusses the effectiveness of cyclin-dependent kinase inhibitors in the treatment of metastatic hormone-positive breast cancer.